Arcutis Biotherapeutics, Inc. ARQT Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $415.62M+10.5% | $376.07M+18.3% | $317.93M+20.7% | $263.47M+23.8% | $212.82M+8.3% | ||
| $37.65M+2.6% | $36.7M+15.0% | $31.91M+11.1% | $28.73M+16.3% | $24.7M+29.1% | ||
| $377.98M+11.4% | $339.38M+18.7% | $286.02M+21.8% | $234.74M+24.8% | $188.12M+6.0% | ||
| 90.9%+0.7pp | 90.2%+0.3pp | 90%+0.9pp | 89.1%+0.7pp | 88.4%-1.9pp | ||
| $90.14M+17.0% | $77.05M+8.4% | $71.08M+0.1% | $70.98M+0.2% | $70.82M-7.3% | ||
| $284.63M+3.7% | $274.55M+8.4% | $253.18M+1.4% | $249.6M+4.6% | $238.6M+4.0% | ||
| $412.41M+6.2% | $388.3M+9.0% | $356.18M+2.0% | $349.3M+4.5% | $334.12M+2.8% | ||
| —— | —— | -$38.25M+55.4% | -$85.84M+29.2% | -$121.3M+5.5% | ||
| $13.47M+11.5% | $12.08M-17.4% | $14.63M-19.7% | $18.22M-19.7% | $22.67M-16.6% | ||
| —— | —— | —— | —— | —— | ||
| $985K-15.9% | $1.17M+14.4% | $1.02M+8.5% | $944K+56.8% | $602K-7.0% | ||
| —— | —— | -$44.32M+52.5% | -$93.27M+28.1% | -$129.72M+7.4% | ||
| —— | —— | -$0.35+52.7% | -$0.74+28.2% | -$1.03+10.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Arcutis Biotherapeutics, Inc.'s profit margins?
- Gross margin is 90.9% and operating margin is -12.0%, with a -13.9% net margin.
- Where does Arcutis Biotherapeutics, Inc.'s income statement data come from?
- Every line is extracted from Arcutis Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.